2.97
+0.1983(+7.16%)
Currency In USD
| Previous Close | 2.77 |
| Open | 2.73 |
| Day High | 3.04 |
| Day Low | 2.59 |
| 52-Week High | 9.25 |
| 52-Week Low | 2.37 |
| Volume | 67,851 |
| Average Volume | 38,869 |
| Market Cap | 3.76M |
| PE | -0.2 |
| EPS | -14.79 |
| Moving Average 50 Days | 3.26 |
| Moving Average 200 Days | 5.14 |
| Change | 0.2 |
If you invested $1000 in Pasithea Therapeutics Corp. (KTTA) since IPO date, it would be worth $41.69 as of December 30, 2024 at a share price of $2.968. Whereas If you bought $1000 worth of Pasithea Therapeutics Corp. (KTTA) shares 2 years ago, it would be worth $231.18 as of December 30, 2024 at a share price of $2.968.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
GlobeNewswire Inc.
Nov 20, 2024 12:02 PM GMT
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities (DLTs) observed to date -- -- No rash observed to date -- MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASD
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Sep 26, 2024 10:44 PM GMT
MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofi
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
GlobeNewswire Inc.
Sep 26, 2024 11:02 AM GMT
-- Single patient in 2mg cohort with stage 3 colon cancer who received 4 prior lines of therapy achieves prolonged stable disease and remains on drug into 6th dosing cycle -- -- No treatment-related adverse events (TRAEs) or dose-limiting toxicities